Needham & Company LLC Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $16.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective decreased by analysts at Needham & Company LLC from $18.00 to $16.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 80.89% from the company’s previous close.

Several other brokerages also recently weighed in on BCRX. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.10.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.19 during midday trading on Wednesday, hitting $8.85. The company had a trading volume of 6,710,668 shares, compared to its average volume of 5,070,783. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of 7.37 and a beta of 0.57. The company’s 50 day simple moving average is $9.03 and its 200 day simple moving average is $7.80. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same quarter last year, the company earned $0.20 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. Analysts anticipate that BioCryst Pharmaceuticals will post 0.26 EPS for the current year.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. The trade was a 27.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC grew its position in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $77,000. Farther Finance Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 8,109 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.